Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Clinical Question·Updated Jul 2, 2026·v1

Role of SBRT in Oligometastatic NSCLC [Gemini 3.1 Pro]

Evidence-based overview of Role of SBRT in metastatic lung cancer.

Moderate Evidence23 references·885 words·4 min read·v1
Radiation Oncologyrole of sbrt in metastatic lung cancer
[[Stereotactic body radiation therapy]] ([[SBRT]]) is an evolving adjunct to systemic therapy in metastatic [[non-small cell lung cancer]] (NSCLC). It is primarily used to consolidate residual [[oligometastatic]] disease in patients responding to [[tyrosine kinase inhibitors]] and is being investigated to augment [[immune checkpoint inhibitors]] by inducing systemic antitumor immune responses.

Deep Dive — Evidence Details

References

  1. [1]

    Cho BC, Lim SM, Lee SH et al.. “MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer.” Lung cancer (Amsterdam, Netherlands) (2026). PMID: 42103553 ↗

    L2RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  2. [2]

    Ghiringhelli F, Lawrence YR, Felip E et al.. “Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study.” Journal for immunotherapy of cancer (2025). PMID: 40759444 ↗

    L1RCTCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, Applicability and Caveats, On the Horizon
  3. [3]

    Zhang R, Chen M, Yin N et al.. “Low-dose radiation and stereotactic body radiotherapy with PD-1 inhibitor sintilimab and chemotherapy for first-line treatment of locally advanced or metastatic squamous lung cancer: protocol for a randomised phase II trial (IHC002 study).” BMJ open (2025). PMID: 40887121 ↗

    L5TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  4. [4]

    Filippi AR, Rulli E, Signorelli D et al.. “Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.” Clinical lung cancer (2025). PMID: 40781023 ↗

    L5TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  5. [5]

    Huang J, Theelen WSME, Belcaid Z et al.. “Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer.” Nature cancer (2025). PMID: 40696153 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  6. [6]

    Chuong MD, Mittauer KE, Bassetti MF et al.. “Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.” International journal of radiation oncology, biology, physics (2025). PMID: 40158734 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  7. [7]

    Keane FK, Yeap BY, Khandekar MJ et al.. “Phase 2 Trial of Consolidative Stereotactic Body Radiation Therapy in Patients With Metastatic Oncogene-driven Non-small Cell Lung Carcinoma Treated With Tyrosine Kinase Inhibitors.” International journal of radiation oncology, biology, physics (2024). PMID: 39577475 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard
  8. [8]

    Levy A, Adebahr S, Hurkmans C et al.. “Stereotactic Body Radiotherapy for Centrally Located Inoperable Early-Stage NSCLC: EORTC 22113-08113 LungTech Phase II Trial Results.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2024). PMID: 38788924 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Background: Evolution of Treatment, Current Evidence and Standard, On the Horizon
  9. [9]

    Franceschini D, Franzese C, Comito T et al.. “Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2024). PMID: 38522597 ↗

    L2TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard, Applicability and Caveats
  10. [10]

    Levy A, Morel D, Texier M et al.. “An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.” Molecular cancer (2024). PMID: 38519913 ↗

    L4TRIAL_NONRANDOMCited in: Bottom Line, Current Evidence and Standard
  11. [11]

    Zeng H, Wang X, Bai H et al.. “Stereotactic body radiation therapy for ultra-central lung malignancies: an updated systematic review and meta-analysis.” Radiation oncology (London, England) (2026). PMID: 42116164 ↗

    L2SR_OBSCited in: Current Evidence and Standard
  12. [12]

    Gooijer SA, Gazendam ASM, Torensma B et al.. “Metastasectomy versus stereotactic body radiotherapy for patients with oligometastatic colorectal lung metastases: a systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2025). PMID: 40300380 ↗

    L2SR_OBSCited in: Current Evidence and Standard
  13. [13]

    Mayinger M, Kotecha R, Sahgal A et al.. “Stereotactic Body Radiotherapy for Lung Oligo-metastases: Systematic Review and International Stereotactic Radiosurgery Society Practice Guidelines.” Lung cancer (Amsterdam, Netherlands) (2023). PMID: 37390723 ↗

    L1GUIDELINECited in: Applicability and Caveats
  14. [14]

    Iyengar P, All S, Berry MF et al.. “Treatment of Oligometastatic Non-Small Cell Lung Cancer: An ASTRO/ESTRO Clinical Practice Guideline.” Practical radiation oncology (2023). PMID: 37294262 ↗

    L1GUIDELINECited in: Applicability and Caveats
  15. [15]

    Simone CB, Bogart JA, Cabrera AR et al.. “Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline.” Practical radiation oncology (2020). PMID: 32222430 ↗

    L1GUIDELINECited in: Applicability and Caveats
  16. [16]

    Tjong MC, Louie AV, Singh AK et al.. “Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung - The Knockout Punch.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2022). PMID: 35221140 ↗

    L5RCTCited in: Applicability and Caveats
  17. [17]

    Bestvina CM, Pointer KB, Karrison T et al.. “A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.” Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2021). PMID: 34500113 ↗

    L1RCTCited in: Applicability and Caveats
  18. [18]

    Zelefsky MJ, Yamada Y, Greco C et al.. “Phase 3 Multi-Center, Prospective, Randomized Trial Comparing Single-Dose 24 Gy Radiation Therapy to a 3-Fraction SBRT Regimen in the Treatment of Oligometastatic Cancer.” International journal of radiation oncology, biology, physics (2021). PMID: 33422612 ↗

    L1RCTCited in: Applicability and Caveats
  19. [19]

    Kim KH, Yoon S, Ahn HK et al.. “A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).” Clinical lung cancer (2022). PMID: 36002368 ↗

    L5TRIAL_NONRANDOMCited in: Applicability and Caveats
  20. [20]

    Navarria P, Baldaccini D, Clerici E et al.. “Stereotactic Body Radiation Therapy for Lung Metastases From Sarcoma in Oligometastatic Patients: A Phase 2 Study.” International journal of radiation oncology, biology, physics (2022). PMID: 35987453 ↗

    L4TRIAL_NONRANDOMCited in: Applicability and Caveats
  21. [21]

    Tsai CJ, Yang JT, Shaverdian N et al.. “Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.” Lancet (London, England) (2023). PMID: 38104577 ↗

    L1RCTCited in: On the Horizon
  22. [22]

    Peng P, Gong J, Zhang Y et al.. “EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2023). PMID: 37105304 ↗

    L1RCTCited in: On the Horizon
  23. [23]

    Bassetti MF, Morris BA, Sethakorn N et al.. “Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.” International journal of radiation oncology, biology, physics (2023). PMID: 38072321 ↗

    L4TRIAL_NONRANDOMCited in: On the Horizon

Revision History

All updates applied to this page

Loading revisions…